Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 4
2020 3
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm.
Juif PE, Dingemanse J, Ufer M. Juif PE, et al. Front Pharmacol. 2021 Feb 4;11:628956. doi: 10.3389/fphar.2020.628956. eCollection 2020. Front Pharmacol. 2021. PMID: 33613288 Free PMC article. Review.
Clazosentan is a potent ET(A) receptor antagonist for intravenous use currently under development for the prevention of aSAH-induced cerebral vasospasm. ...In summary, clazosentan has a pharmacokinetic, pharmacodynamic, and safety profile suitable to b …
Clazosentan is a potent ET(A) receptor antagonist for intravenous use currently under development for the prevention of aSAH-induced …
The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Bruder N, Higashida R, Santin-Janin H, Dubois C, Aldrich EF, Marr A, Roux S, Mayer SA. Bruder N, et al. BMC Neurol. 2022 Dec 20;22(1):492. doi: 10.1186/s12883-022-03002-8. BMC Neurol. 2022. PMID: 36539711 Free PMC article. Clinical Trial.
METHODS: REACT is a prospective, multicenter, randomized phase 3 study that is planned to enroll 400 patients with documented aSAH from a ruptured cerebral aneurysm, randomized 1:1 to 15 mg/hour intravenous clazosentan vs. placebo, in approximately 100 sites and 15 …
METHODS: REACT is a prospective, multicenter, randomized phase 3 study that is planned to enroll 400 patients with documented aSAH from a ru …
Economic and Humanistic Burden of Cerebral Vasospasm and Its Related Complications after Aneurysmal Subarachnoid Hemorrhage: A Systematic Literature Review.
Thompson JC, Chalet FX, Manalastas EJ, Hawkins N, Sarri G, Talbot DA. Thompson JC, et al. Neurol Ther. 2022 Jun;11(2):597-620. doi: 10.1007/s40120-022-00348-6. Epub 2022 Apr 20. Neurol Ther. 2022. PMID: 35441974 Free PMC article. Review.
INTRODUCTION: Cerebral vasospasm (VSP) is the leading risk factor of neurological deterioration (i.e., delayed cerebral ischemia [DCI] and cerebral infarction) after aneurysmal subarachnoid hemorrhage (aSAH) and a cause of morbidity and mortality. ...O …
INTRODUCTION: Cerebral vasospasm (VSP) is the leading risk factor of neurological deterioration (i.e., delayed cerebral …
Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
Higashida RT, Bruder N, Gupta R, Guzman R, Hmissi A, Marr A, Mayer SA, Roux S, Weidauer S, Aldrich EF. Higashida RT, et al. World Neurosurg. 2019 Aug;128:e639-e648. doi: 10.1016/j.wneu.2019.04.222. Epub 2019 May 2. World Neurosurg. 2019. PMID: 31054336 Clinical Trial.
The primary efficacy endpoint was the reversal of global cerebral vasospasm in large cerebral artery segments 3 hours after clazosentan initiation. ...This observation supported the inclusion of patients with established vasospasm in the ongoing …
The primary efficacy endpoint was the reversal of global cerebral vasospasm in large cerebral artery segments 3 hours a …
Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
Mayer SA, Aldrich EF, Bruder N, Hmissi A, Macdonald RL, Viarasilpa T, Marr A, Roux S, Higashida RT. Mayer SA, et al. Stroke. 2019 Oct;50(10):2738-2744. doi: 10.1161/STROKEAHA.119.025682. Epub 2019 Aug 9. Stroke. 2019. PMID: 31394993
Background and Purpose- Clazosentan, an endothelin receptor antagonist, has been shown to reduce angiographic vasospasm and vasospasm-related morbidity after aneurysmal subarachnoid hemorrhage (SAH), although no effect on long-term functional outcome has been …
Background and Purpose- Clazosentan, an endothelin receptor antagonist, has been shown to reduce angiographic vasospasm and …
Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage.
Aldrich EF, Higashida R, Hmissi A, Le EJ, Macdonald RL, Marr A, Mayer SA, Roux S, Bruder N. Aldrich EF, et al. J Neurosurg. 2020 May 22;134(5):1553-1561. doi: 10.3171/2020.3.JNS193400. J Neurosurg. 2020. PMID: 32442971
Individual event rates were 7.5% versus 2.5% for all-cause death, 19.4% versus 6.8% for new cerebral infarct, 28.2% versus 9.4% for delayed ischemic neurological deficit, and 24.8% versus 10.8% for rescue therapy due to cerebral vasospasm, respectively. ...CO …
Individual event rates were 7.5% versus 2.5% for all-cause death, 19.4% versus 6.8% for new cerebral infarct, 28.2% versus 9.4% for d …
[Pharmacological Profile and Clinical Study Results of endothelin receptor antagonist, Clazosentan Sodium (PIVLAZ() I.V. Infusion liquid 150 mg)].
Takahashi S, Tanaka H. Takahashi S, et al. Nihon Yakurigaku Zasshi. 2022;157(6):464-473. doi: 10.1254/fpj.22065. Nihon Yakurigaku Zasshi. 2022. PMID: 36328562 Clinical Trial. Japanese.
Of patients with cerebral vasospasm, 17 to 40% experience delayed ischemic neurological deficits and about half of them develop cerebral infarction. ...In the clinical study, the incidence of cerebral vasospasm-related morbidity and all-cause mo …
Of patients with cerebral vasospasm, 17 to 40% experience delayed ischemic neurological deficits and about half of them develo …
Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.
Juif PE, Dingemanse J, Voors-Pette C, Ufer M. Juif PE, et al. AAPS J. 2020 Aug 3;22(5):103. doi: 10.1208/s12248-020-00485-6. AAPS J. 2020. PMID: 32748293 Clinical Trial.
This study investigated the potential QT liability of the selective endothelin-1 A receptor antagonist clazosentan at a therapeutic (20 mg/h) and supratherapeutic (60 mg/h) intravenous (i.v.) dose. ...By contrast, there was no association with other adverse events, food in …
This study investigated the potential QT liability of the selective endothelin-1 A receptor antagonist clazosentan at a therapeutic ( …
Clinical Burden of Angiographic Vasospasm and Its Complications After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review.
Chalet FX, Briasoulis O, Manalastas EJ, Talbot DA, Thompson JC, Macdonald RL. Chalet FX, et al. Neurol Ther. 2023 Apr;12(2):371-390. doi: 10.1007/s40120-022-00436-7. Epub 2023 Jan 7. Neurol Ther. 2023. PMID: 36609962 Free PMC article. Review.
INTRODUCTION: Angiographic vasospasm (VSP), the narrowing of intracranial arteries, is a complication of aneurysmal subarachnoid hemorrhage (aSAH) and often results in delayed cerebral ischemia (DCI) and cerebral infarction. ...The considerable clinica …
INTRODUCTION: Angiographic vasospasm (VSP), the narrowing of intracranial arteries, is a complication of aneurysmal subarachno …
Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.
Juif PE, Voors-Pette C, Ufer M, Dogterom P, Dingemanse J. Juif PE, et al. Clin Transl Sci. 2019 Sep;12(5):440-444. doi: 10.1111/cts.12639. Epub 2019 May 6. Clin Transl Sci. 2019. PMID: 31004470 Free PMC article. Clinical Trial.
Clazosentan is a selective endothelin A receptor antagonist in development for the prevention and treatment of vasospasm postsubarachnoid hemorrhage. ...A similar pattern but a higher incidence and frequency of adverse events were observed when clazosentan wa …
Clazosentan is a selective endothelin A receptor antagonist in development for the prevention and treatment of vasospasm posts …
12 results